Health
Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care
WALTHAM, Mass., December 18, 2025--Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care.
About this update from Thermo Fisher Scientific Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1590,"height":341,"url":"https://media.zenfs.com/en/business-wire.com/3d40f4b5873a0db2410644407e1e018c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/81giimjpeKA17Oe4GRJ.Pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3d40f4b5873a0db2410644407e1e018c","width":960,"height":206},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/qPNJwely8LtXzb_7YRlszA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3d40f4b5873a0db2410644407e1e018c","width":1200,"height":257}},"lazy":false},{"type":"text","content":"WALTHAM, Mass., December 18, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the enrollment of the first patient in the new PPD™ CorEvitas™ Alzheimer’s Disease Registry. Designed as an international, multi-country initiative, the registry will generate robust, harmonized, fit-for-purpose real-world data under a common global protocol to support novel evaluations of drug safety and effectiveness that are critical for regulator, clinician, patient and caregiver communities.","length":535,"tagName":"p"},{"type":"text","content":"Its longitudinal design, coupled with clinician-reported data from routine practice, will generate a comprehensive understanding of Alzheimer’s therapy outcomes in real-world settings. The registry will illuminate long-term safety, treatment patterns and the evolving use of approved therapies, while also helping to identify unmet medical needs, clarify the disease’s impact on patients, and evaluate the clinical outcomes associated with existing treatment options.","length":467,"tagName":"p"},{"type":"text","content":"Alzheimer’s disease is a progressive neurodegenerative disorder that gradually damages brain cells, impairing memory, language, decision-making abilities and ultimately, the ability to perform daily tasks. An estimated 7.2 million Americans age 65 and older are living with Alzheimer’s1, a number expected to double by 20502. As a leading cause of death in the United States2, the disease represents a significant public health challenge and underscores the need for rigorous evidence to guide therapeutic develo...